LifeMD (LFMD) to Post Quarterly Earnings on Wednesday

LifeMD (NASDAQ:LFMD) is projected to post its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.1457) per share and revenue of $49.1570 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). LifeMD had a negative return on equity of 150.88% and a net margin of 2.37%.The firm had revenue of $50.16 million during the quarter, compared to analyst estimates of $48.84 million. On average, analysts expect LifeMD to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

LifeMD Stock Performance

Shares of LFMD opened at $3.84 on Wednesday. LifeMD has a one year low of $2.56 and a one year high of $12.72. The stock has a market capitalization of $185.70 million, a price-to-earnings ratio of 76.82 and a beta of 1.99. The stock has a 50 day moving average price of $4.50 and a 200 day moving average price of $3.99.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of LifeMD by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock worth $270,000 after purchasing an additional 2,235 shares during the last quarter. Creative Planning acquired a new stake in LifeMD in the 2nd quarter valued at approximately $272,000. JPMorgan Chase & Co. raised its position in LifeMD by 581.2% in the second quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock valued at $5,619,000 after purchasing an additional 352,004 shares during the period. Legal & General Group Plc lifted its stake in LifeMD by 187.4% during the second quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock worth $138,000 after purchasing an additional 6,614 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in LifeMD by 8.7% during the second quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock worth $730,000 after purchasing an additional 4,281 shares in the last quarter. 35.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on LFMD. Wall Street Zen cut shares of LifeMD from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. BTIG Research reissued a “buy” rating and issued a $10.00 price target on shares of LifeMD in a research note on Monday, May 4th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of LifeMD in a research note on Tuesday, May 26th. UBS Group reiterated a “buy” rating on shares of LifeMD in a report on Wednesday, May 27th. Finally, Weiss Ratings upgraded LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a report on Thursday, May 7th. Eight research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.14.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.